Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

A comparative network analysis of eating disorder psychopathology and co-occurring depression and anxiety symptoms before and after treatment.

Smith KE, Mason TB, Crosby RD, Cao L, Leonard RC, Wetterneck CT, Smith BER, Farrell NR, Riemann BC, Wonderlich SA, Moessner M.

Psychol Med. 2018 Apr 15:1-11. doi: 10.1017/S0033291718000867. [Epub ahead of print]

PMID:
29655386
2.

Affective predictors of the severity and change in eating psychopathology in residential eating disorder treatment: The role of social anxiety.

Smith KE, Mason TB, Leonard RC, Wetterneck CT, Smith BER, Farrell NR, Riemann BC.

Eat Disord. 2018 Jan-Feb;26(1):66-78. doi: 10.1080/10640266.2018.1418314.

PMID:
29384466
3.

The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.

Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF.

Eur J Cancer. 2017 Dec;87:58-64. doi: 10.1016/j.ejca.2017.10.001. Epub 2017 Nov 5.

4.

Predictors of illness anxiety symptoms in patients with obsessive compulsive disorder.

Reuman L, Jacoby RJ, Blakey SM, Riemann BC, Leonard RC, Abramowitz JS.

Psychiatry Res. 2017 Oct;256:417-422. doi: 10.1016/j.psychres.2017.07.012. Epub 2017 Jul 5.

PMID:
28697487
5.

Anxiety sensitivity as a predictor of outcome in the treatment of obsessive-compulsive disorder.

Blakey SM, Abramowitz JS, Reuman L, Leonard RC, Riemann BC.

J Behav Ther Exp Psychiatry. 2017 Dec;57:113-117. doi: 10.1016/j.jbtep.2017.05.003. Epub 2017 May 6.

PMID:
28505489
6.

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ; tAnGo trial collaborators.

Lancet Oncol. 2017 Jun;18(6):755-769. doi: 10.1016/S1470-2045(17)30319-4. Epub 2017 May 4.

PMID:
28479233
7.

GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.

Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE, Anderson RA; Anglo Celtic Collaborative Oncology Group and National Cancer Research Institute Trialists.

Ann Oncol. 2017 Aug 1;28(8):1811-1816. doi: 10.1093/annonc/mdx184.

PMID:
28472240
8.

Male clinical norms and sex differences on the Eating Disorder Inventory (EDI) and Eating Disorder Examination Questionnaire (EDE-Q).

Smith KE, Mason TB, Murray SB, Griffiths S, Leonard RC, Wetterneck CT, Smith BER, Farrell NR, Riemann BC, Lavender JM.

Int J Eat Disord. 2017 Jul;50(7):769-775. doi: 10.1002/eat.22716. Epub 2017 Apr 24.

PMID:
28436086
9.

A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN.

Leonard RC, Mansi JL, Keerie C, Yellowlees A, Crawford S, Benstead K, Matthew R, Adamson D, Chan S, Grieve R; Anglo-Celtic Collaborative Oncology Group.

Ann Oncol. 2015 Dec;26(12):2437-41. doi: 10.1093/annonc/mdv389. Epub 2015 Sep 28.

PMID:
26416895
10.

Residential treatment outcomes for adolescents with obsessive-compulsive disorder.

Leonard RC, Franklin ME, Wetterneck CT, Riemann BC, Simpson HB, Kinnear K, Cahill SP, Lake PM.

Psychother Res. 2016 Nov;26(6):727-36. doi: 10.1080/10503307.2015.1065022. Epub 2015 Aug 26.

11.

Investigating Treatment Outcomes Across OCD Symptom Dimensions in a Clinical Sample of OCD Patients.

Chase T, Wetterneck CT, Bartsch RA, Leonard RC, Riemann BC.

Cogn Behav Ther. 2015;44(5):365-76. doi: 10.1080/16506073.2015.1015162. Epub 2015 Feb 26.

PMID:
25715733
12.

Secondary Psychometric Examination of the Dimensional Obsessive-Compulsive Scale: Classical Testing, Item Response Theory, and Differential Item Functioning.

Thibodeau MA, Leonard RC, Abramowitz JS, Riemann BC.

Assessment. 2015 Dec;22(6):681-9. doi: 10.1177/1073191114559123. Epub 2014 Nov 24.

PMID:
25422521
13.

Predictors of quality of life and functional impairment in obsessive-compulsive disorder.

Jacoby RJ, Leonard RC, Riemann BC, Abramowitz JS.

Compr Psychiatry. 2014 Jul;55(5):1195-202. doi: 10.1016/j.comppsych.2014.03.011. Epub 2014 Mar 26.

PMID:
24746527
14.

Effects of homograph meaning frequency on semantic satiation.

Black SR, Leonard RC, Willis S, Burton P, McCown S, Lookadoo R, Wayde E.

Can J Exp Psychol. 2013 Sep;67(3):175-87. doi: 10.1037/a0033838.

PMID:
24041302
15.

Just to be certain: Confirming the factor structure of the intolerance of uncertainty scale in patients with obsessive-compulsive disorder.

Jacoby RJ, Fabricant LE, Leonard RC, Riemann BC, Abramowitz JS.

J Anxiety Disord. 2013 Jun;27(5):535-42. doi: 10.1016/j.janxdis.2013.07.008. Epub 2013 Aug 6.

PMID:
23973743
16.

Job stress and dyadic synchrony in police marriages: a preliminary investigation.

Roberts NA, Leonard RC, Butler EA, Levenson RW, Kanter JW.

Fam Process. 2013 Jun;52(2):271-83. doi: 10.1111/j.1545-5300.2012.01415.x. Epub 2012 Sep 20.

17.

Treatment of obsessive-compulsive disorder complicated by comorbid eating disorders.

Simpson HB, Wetterneck CT, Cahill SP, Steinglass JE, Franklin ME, Leonard RC, Weltzin TE, Riemann BC.

Cogn Behav Ther. 2013;42(1):64-76. doi: 10.1080/16506073.2012.751124. Epub 2013 Jan 15.

18.

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.

Earl HM, Hiller L, Dunn JA, Vallier AL, Bowden SJ, Jordan SD, Blows F, Munro A, Bathers S, Grieve R, Spooner DA, Agrawal R, Fernando I, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, McAdam K, Foster L, Leonard RC, Twelves CJ, Cameron D, Bartlett JM, Pharoah P, Provenzano E, Caldas C, Poole CJ; NEAT Investigators and the SCTBG.

Br J Cancer. 2012 Oct 9;107(8):1257-67. doi: 10.1038/bjc.2012.370. Epub 2012 Sep 11.

19.

Aging, imagery, and the bizarreness effect.

Black SR, McCown S, Lookadoo RL, Leonard RC, Kelley M, DeCoster J, Wayde E, Spence SA.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2012 Sep;19(5):566-91. doi: 10.1080/13825585.2011.639868. Epub 2012 Jan 17.

PMID:
22248375
20.

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T.

J Clin Oncol. 2011 Aug 20;29(24):3214-23. doi: 10.1200/JCO.2010.32.5910. Epub 2011 Jul 18.

21.

Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.

Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Evans TR.

Breast Cancer Res Treat. 2010 Aug;122(3):787-94. doi: 10.1007/s10549-010-0989-6. Epub 2010 Jun 18.

PMID:
20559708
22.

Effect of patient age on management decisions in breast cancer: consensus from a national consultation.

Leonard RC, Barrett-Lee PJ, Gosney MA, Willett AM, Reed MW, Hammond PJ.

Oncologist. 2010;15(7):657-64. doi: 10.1634/theoncologist.2009-0284. Epub 2010 Jun 15.

23.

Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).

Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S.

Breast. 2009 Aug;18(4):218-24. doi: 10.1016/j.breast.2009.05.004. Epub 2009 Aug 4. Review.

PMID:
19656681
24.

What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

Aapro M, Barnadas A, Leonard RC, Marangolo M, Untch M, Ukarma L, Burger HU, Scherhag A, Osterwalder B.

Eur J Cancer. 2009 Nov;45(17):2984-91. doi: 10.1016/j.ejca.2009.06.031. Epub 2009 Jul 29.

PMID:
19646862
25.

Ischaemic heart disease mortality study among workers with occupational exposure to ammonium perfluorooctanoate.

Sakr CJ, Symons JM, Kreckmann KH, Leonard RC.

Occup Environ Med. 2009 Oct;66(10):699-703. doi: 10.1136/oem.2008.041582. Epub 2009 Jun 23.

PMID:
19553230
26.

Estimation and validation of biomarker-based exposures for historical ammonium perfluorooctanoate.

Kreckmann KH, Sakr CJ, Leonard RC, Dawson BJ.

J Occup Environ Hyg. 2009 Sep;6(9):511-6. doi: 10.1080/15459620903025483.

PMID:
19504402
27.

Capecitabine and docetaxel combination for the treatment of breast cancer.

Morishita M, Leonard RC.

Womens Health (Lond). 2008 Jan;4:11-22. doi: 10.2217/17455057.4.1.11. Review.

PMID:
19072447
28.

Breast cancer in the elderly.

Thomas GA, Leonard RC.

Clin Oncol (R Coll Radiol). 2009 Mar;21(2):79-80. doi: 10.1016/j.clon.2008.11.011. Epub 2008 Dec 13. No abstract available.

PMID:
19071001
29.

How age affects the biology of breast cancer.

Thomas GA, Leonard RC.

Clin Oncol (R Coll Radiol). 2009 Mar;21(2):81-5. doi: 10.1016/j.clon.2008.11.006. Epub 2008 Dec 13.

PMID:
19071000
30.

Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy.

Morishita M, Leonard RC.

Expert Opin Biol Ther. 2008 Jul;8(7):993-1001. doi: 10.1517/14712598.8.7.993 . Review.

PMID:
18549328
31.

Mortality among workers exposed to acrylonitrile in fiber production: an update.

Symons JM, Kreckmann KH, Sakr CJ, Kaplan AM, Leonard RC.

J Occup Environ Med. 2008 May;50(5):550-60. doi: 10.1097/JOM.0b013e318162f640.

PMID:
18469624
32.

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU.

J Clin Oncol. 2008 Feb 1;26(4):592-8. doi: 10.1200/JCO.2007.11.5378.

PMID:
18235117
33.
34.

Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers.

Leonard RC, Kreckmann KH, Sakr CJ, Symons JM.

Ann Epidemiol. 2008 Jan;18(1):15-22. Epub 2007 Sep 27.

PMID:
17900928
35.

Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate.

Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR.

J Occup Environ Med. 2007 Aug;49(8):872-9. Erratum in: J Occup Environ Med. 2007 Nov;49(11):1294.

PMID:
17693785
36.

The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.

Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas GA, Leonard RC.

Acta Oncol. 2007;46(5):669-77.

PMID:
17562444
37.

Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer.

Malinovszky KM, Gould A, Foster E, Cameron D, Humphreys A, Crown J, Leonard RC; Anglo Celtic Co-operative Oncology Group.

Br J Cancer. 2006 Dec 18;95(12):1626-31.

38.

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ; NEAT Investigators and the SCTBG.

N Engl J Med. 2006 Nov 2;355(18):1851-62.

39.

Chemical process based reconstruction of exposures for an epidemiological study. III. Analysis of industrial hygiene samples.

Hall TA, Esmen NA, Jones EP, Basara H, Phillips ML, Marsh GM, Youk AO, Buchanich JM, Leonard RC.

Chem Biol Interact. 2007 Mar 20;166(1-3):277-84. Epub 2006 Sep 16.

PMID:
17074311
40.

Profiling the breast cancer proteome--the new tool of the future?

Grassl J, Morishita M, Lewis PD, Leonard RC, Thomas G.

Clin Oncol (R Coll Radiol). 2006 Oct;18(8):581-6. Review. No abstract available.

PMID:
17051946
41.

Comparison of standardized mortality ratios (SMRs) obtained from use of reference populations based on a company-wide registry cohort to SMRs calculated against local and national rates.

Leonard RC, Kreckmann KH, Lineker GA, Marsh G, Buchanich J, Youk A.

Chem Biol Interact. 2007 Mar 20;166(1-3):317-22. Epub 2006 Sep 10.

PMID:
17011535
42.

Treatment options for older woman with early breast cancer.

Moe MM, Pwint TP, Leonard RC.

Expert Rev Anticancer Ther. 2006 Jun;6(6):941-50. Review.

PMID:
16761938
43.

Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.

Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L, Leonard RC.

Oncology. 2005;69(6):471-7. Epub 2006 Jan 12.

PMID:
16410685
44.

Adjuvant hormonal therapy in early breast cancer.

Kumar S, Leonard RC.

Oncology (Williston Park). 2005 Oct;19(11):1425-8, 1433; discussion 1433-41, 1444-6. Review.

45.

Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.

Bertelli G, Garrone O, Bertolotti L, Occelli M, Conforti S, Marzano N, Febbraro A, Carlini P, Liossi C, Del Mastro L, Leonard RC.

Oncology. 2005;68(4-6):364-70. Epub 2005 Jul 11.

PMID:
16020964
46.

Chemotherapy for older women with early breast cancer.

Leonard RC, Malinovszky KM.

Clin Oncol (R Coll Radiol). 2005 Jun;17(4):244-8. Review.

PMID:
15997919
47.

Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.

Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Mansi JL.

J Clin Oncol. 2005 May 1;23(13):2988-95.

PMID:
15860854
48.

Management of anaemia in patients with breast cancer: role of epoetin.

Leonard RC, Untch M, Von Koch F.

Ann Oncol. 2005 May;16(5):817-24. Epub 2005 Apr 7. Review.

PMID:
15817603
49.

A comparison of self-reported satisfaction between adolescents treated in a "teenage" unit with those treated in adult or paediatric units.

Reynolds BC, Windebank KP, Leonard RC, Wallace WH.

Pediatr Blood Cancer. 2005 Mar;44(3):259-63.

PMID:
15514917
50.

Breast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET).

Malinovszky KM, Cameron D, Douglas S, Love C, Leonard T, Dixon JM, Hopwood P, Leonard RC.

Breast. 2004 Oct;13(5):363-8.

PMID:
15454190

Supplemental Content

Loading ...
Support Center